Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis.
Montesinos P, Díaz-Mediavilla J, Debén G, Prates V, Tormo M, Rubio V, Pérez I, Fernández I, Viguria M, Rayón C, González J, de la Serna J, Esteve J, Bergua JM, Rivas C, González M, González JD, Negri S, Brunet S, Lowenberg B, Sanz MA. Montesinos P, et al. Haematologica. 2009 Sep;94(9):1242-9. doi: 10.3324/haematol.2009.007872. Epub 2009 Jul 16. Haematologica. 2009. PMID: 19608685 Free PMC article. Clinical Trial.
All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia.
Sanz MA, Vellenga E, Rayón C, Díaz-Mediavilla J, Rivas C, Amutio E, Arias J, Debén G, Novo A, Bergua J, de la Serna J, Bueno J, Negri S, Beltrán de Heredia JM, Martín G. Sanz MA, et al. Blood. 2004 Dec 1;104(12):3490-3. doi: 10.1182/blood-2004-04-1642. Epub 2004 Aug 3. Blood. 2004. PMID: 15292063 Free article. Clinical Trial.
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.
de la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, Esteve J, Bergua JM, Milone G, Debén G, Rivas C, González M, Tormo M, Díaz-Mediavilla J, González JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA. de la Serna J, et al. Blood. 2008 Apr 1;111(7):3395-402. doi: 10.1182/blood-2007-07-100669. Epub 2008 Jan 14. Blood. 2008. PMID: 18195095 Free article. Clinical Trial.
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors.
Montesinos P, Bergua JM, Vellenga E, Rayón C, Parody R, de la Serna J, León A, Esteve J, Milone G, Debén G, Rivas C, González M, Tormo M, Díaz-Mediavilla J, González JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA. Montesinos P, et al. Blood. 2009 Jan 22;113(4):775-83. doi: 10.1182/blood-2008-07-168617. Epub 2008 Oct 22. Blood. 2009. PMID: 18945964 Free article. Clinical Trial.
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.
Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, González J, Díaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, González JD, Lowenberg B; PETHEMA and HOVON Groups. Sanz MA, et al. Blood. 2010 Jun 24;115(25):5137-46. doi: 10.1182/blood-2010-01-266007. Epub 2010 Apr 14. Blood. 2010. PMID: 20393132 Free article. Clinical Trial.
Maternal and fetal outcomes in pregnant women with acute promyelocytic leukemia.
Sanz MA, Montesinos P, Casale MF, Díaz-Mediavilla J, Jiménez S, Fernández I, Fernández P, González-Campos J, González JD, Herrera P, de Lisa E, Olave T, Rojas R, Salamero O, Sayas MJ, Pellicer A, Perales A. Sanz MA, et al. Among authors: diaz mediavilla j. Ann Hematol. 2015 Aug;94(8):1357-61. doi: 10.1007/s00277-015-2372-5. Epub 2015 Apr 25. Ann Hematol. 2015. PMID: 25911134
Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.
Chillón MC, Santamaría C, García-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Marín L, Caballero MD, Vidriales MB, Ramos F, Bernal T, Díaz-Mediavilla J, García de Coca A, Peñarrubia MJ, Queizán JA, Giraldo P, San Miguel JF, González M. Chillón MC, et al. Haematologica. 2010 May;95(5):745-51. doi: 10.3324/haematol.2009.015073. Epub 2010 Feb 4. Haematologica. 2010. PMID: 20133893 Free PMC article.
Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia.
Vidriales MB, Pérez-López E, Pegenaute C, Castellanos M, Pérez JJ, Chandía M, Díaz-Mediavilla J, Rayón C, de Las Heras N, Fernández-Abellán P, Cabezudo M, de Coca AG, Alonso JM, Olivier C, Hernández-Rivas JM, Montesinos P, Fernández R, García-Suárez J, García M, Sayas MJ, Paiva B, González M, Orfao A, San Miguel JF; PETHEMA Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group. Vidriales MB, et al. Among authors: diaz mediavilla j. Leuk Res. 2016 Jan;40:1-9. doi: 10.1016/j.leukres.2015.10.002. Epub 2015 Oct 22. Leuk Res. 2016. PMID: 26598032
BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML).
Santamaría C, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Mateos MV, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizán JA, Rodríguez JN, Puig N, Balanzategui A, Sarasquete ME, Alcoceba M, Díaz-Mediavilla J, San Miguel J, González M. Santamaría C, et al. Ann Hematol. 2010 May;89(5):453-8. doi: 10.1007/s00277-009-0864-x. Epub 2009 Nov 27. Ann Hematol. 2010. PMID: 19943049
124 results